Trials / Completed
CompletedNCT00073749
Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma
A Phase 1 Study Of Cmc-544 Administered As A Single Agent In Subjects With B-cell Non- Hodgkin's Lymphoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 79 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
To determine the Maximum Tolerated Dose (MTD), the tolerability, and the initial safety profile of CMC-544 in subjects with B-cell Non-Hodgkin's Lymphoma (NHL).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Inotuzumab ozogamicin [CMC-544] | CMC-544, IV, dose escalation trial |
Timeline
- Start date
- 2003-08-01
- Primary completion
- 2010-12-01
- Completion
- 2010-12-01
- First posted
- 2003-12-05
- Last updated
- 2018-12-17
- Results posted
- 2018-10-26
Locations
22 sites across 7 countries: United States, Belgium, France, Germany, Spain, Switzerland, United Kingdom
Source: ClinicalTrials.gov record NCT00073749. Inclusion in this directory is not an endorsement.